
Please try another search
YTD | 3M | 1Y | 3Y | 5Y | 10Y | |
---|---|---|---|---|---|---|
Growth of 1000 | 1019 | 1009 | 1071 | 1034 | 1011 | 1274 |
Fund Return | 1.89% | 0.93% | 7.12% | 1.11% | 0.22% | 2.45% |
Place in category | 406 | 257 | 222 | 192 | 188 | 58 |
% in Category | 65 | 47 | 40 | 57 | 79 | 56 |
Name | Rating | Total Assets | YTD% | 3Y% | 10Y% | |
---|---|---|---|---|---|---|
Swisscanto LU Bond Secured HiYld AT | 218.81M | 8.12 | 4.29 | 4.09 | ||
Swisscanto LU Bond Secured HiYld GT | 218.81M | 9.10 | 5.23 | 4.97 | ||
Swisscanto LU Bond Secured HiYld AA | 218.81M | 8.12 | 4.30 | 4.09 | ||
Swisscanto LU Bond GlblCnvrtble HBU | 146.43M | 2.61 | 1.46 | 3.57 | ||
SWBond Fund Global Convertible H US | 146.43M | 9.24 | -0.10 | 4.34 |
Name | Rating | Total Assets | YTD% | 3Y% | 10Y% | |
---|---|---|---|---|---|---|
AvivaInvGlblInvGradeCorpBondIUSDAcc | 7.06B | 3.40 | -1.33 | - | ||
JPMorgan Glbl Corp Bond C Acc USD | 6.32B | 1.95 | 1.40 | 2.64 | ||
JPMorgan Glbl Corp Bond I Acc USD | 6.32B | 1.95 | 1.44 | 2.68 | ||
JPMorgan GlblCorpBond C dist USD | 6.32B | 0.57 | 0.18 | 2.48 | ||
LU1143726096 | 3B | 3.17 | -1.60 | 2.75 |
Name | ISIN | Weight % | Last | Change % | |
---|---|---|---|---|---|
SWC (LU) BF Resp. Crp Hybrid STH USD | LU2364759055 | 5.17 | - | - | |
Bank of America Corp. 6.204% | - | 1.45 | - | - | |
UnitedHealth Group Inc. 5.875% | - | 0.95 | - | - | |
Citibank, N.A. 5.57% | - | 0.95 | - | - | |
Takeda Pharmaceutical Co Ltd. 5.65% | - | 0.91 | - | - |
Type | Daily | Weekly | Monthly |
---|---|---|---|
Moving Averages | Buy | Buy | Buy |
Technical Indicators | BUY | Strong Buy | Strong Buy |
Summary | Buy | Strong Buy | Strong Buy |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review